title: Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.
abstract: Fibroblast growth factor receptor 4 (FGFR4) is a transmembrane receptor with ligand-induced tyrosine kinase activity and is involved in various biological and pathological processes. Several polymorphisms of FGFR4 are associated with the incidence and mortality of numerous cancers, including prostate cancer. In this study, we investigated whether the polymorphisms of FGFR4 influence the biochemical recurrence of prostate cancer in Chinese men after radical prostatectomy. Three common polymorphisms (rs1966265, rs2011077, and rs351855) of FGFR4 were genotyped from 346 patients with prostate cancer by using the Sequenom MassARRAY system. Kaplan-Meier curves and Cox proportional hazard models were used for survival analysis. Results showed biochemical recurrence (BCR) free survival was significantly affected by the genotypes of rs351855 but not influenced by rs1966265 and rs2011077. After adjusting for other variables in multivariable analysis, patients with rs351855 AA/AG genotypes showed significantly worse BCR-free survival than those with the GG genotype (HR = 1.873; 95% CI, 1.209-2.901; P = 0.005). Hence, FGFR4 rs351855 could be a novel independent prognostic factor of BCR after radical prostatectomy in the Chinese population. This functional polymorphism may also provide a basis for surveillance programs. Additional large-scale studies must be performed to validate the significance of this polymorphism in prostate cancer.
authors.affiliation: Department of Urology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Luyao
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Urology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Zhengwei
authors.initials: Z
authors.lastname: Lei
authors.affiliation: Department of Urology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Ma
authors.affiliation: Department of Urology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Qingbo
authors.initials: Q
authors.lastname: Huang
authors.affiliation: Department of Urology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Urology, Puai Hospital, Wuhan, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Urology, Puai Hospital, Wuhan, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Hao
authors.affiliation: Department of Urology, Puai Hospital, Wuhan, China.
authors.forename: Minggang
authors.initials: M
authors.lastname: Yang
authors.affiliation: Department of Urology, Puai Hospital, Wuhan, China.
authors.forename: Xuetao
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Urology, Puai Hospital, Wuhan, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Urology, Puai Hospital, Wuhan, China.
authors.forename: Gongxue
authors.initials: G
authors.lastname: Liu
authors.affiliation: Department of Urology, Puai Hospital, Wuhan, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Zheng
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor; D002681:China / Q000453:epidemiology; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016016:Proportional Hazards Models; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D051499:Receptor, Fibroblast Growth Factor, Type 4 / Q000235:genetics*; D012008:Recurrence
chemical_list: D014408:Biomarkers, Tumor; D051499:Receptor, Fibroblast Growth Factor, Type 4